Research and development - Today Stories

Novel non-viral gene delivery platform to help advance tissue repair following orthopaedic surgery Funding from Innovate UK’s Transforming Medicines Manufacturing programme supporting innovative technologies for intracellular drug delivery London, UK, and Nottingham, UK, 31 August 2023: TherageniX, a University of Nottingham spin out pioneering a dry powder gene therapy formulation for bone graft augmentation, and its collaborator, the University of Nottingham, have been awarded a £995,000 grant from Innovate UK, the UK’s innovation agency. The funding will support the development of the Company’s gene therapy in a powder, a non-viral gene delivery system to improve tissue regeneration following surgery. TherageniX will initially focus on orthopaedic applications, with the aim of improvi…

Powered by Sanofi, a new BioMed X research team will develop a computational platform designed to accelerate drug development. Heidelberg, June 29, 2023. BioMed X, a German independent research institute, announces the start of its first research project in collaboration with Sanofi: “Next Generation Virtual Patient Engine for Clinical Translation of Drug Candidates” (VPE). The end goal of this research project is to develop a versatile computational platform that can predict the efficacy of first- or best-in-class drug candidates in virtual patient populations at unprecedented accuracy, thereby addressing one of the most critical bottlenecks of the pharmaceutical industry today: a 90% failure rate of new drug candidates during clinical development. The new research team will be led by D…

Sanofi, Meningitis Research Foundation, and the Confederation of Meningitis Organisations ignite a global awareness initiative against meningitis with launch of The Meningitis Flag Paris, August 28, 2023. Today, Meningitis Research Foundation, the Confederation of Meningitis Organisations (CoMO) and Sanofi join forces to launch ‘The Meningitis Flag’, a global initiative to raise awareness in the fight against meningitis. With the Paris 2024 Paralympic Games opening in exactly one year, and with the support of para-athletes Ellie Challis (Great Britain), Théo Curin (France), and Davide Morana (Italy), this unique global campaign seeks to increase understanding of a disease that remains one of the world’s largest infectious disease killers, and yet is largely preventable.1,2 Despite major pr…

23 August 2023: Kadans Science Partner (“Kadans”) is set to welcome AviadoBio to its recently completed wet lab innovation and flexible workspace centre at 20 Water Street in Canary Wharf. AviadoBio, a pioneering gene therapy company developing and delivering transformative medicines for neurodegenerative disorders, will establish laboratory and office presence at the Innovation Centre. AviadoBio will begin working at Kadans’ London Innovation Centre following the recent completion of their wet-lab Innovation Centre at levels four and five at 20 Water Street. The company will be joining the Kadans’ growing European ecosystem of over 450 tenants including Cytiva, Akamis Bio, GeneFirst and Sherlock Bioscience. Lisa Deschamps, CEO of AviadoBio, said: “We are very excited about our new partner…

Strategic Partnership Aims to Revolutionize Cancer Screening and Enhance Healthcare Outcomes, Bringing Innovative Genetic Testing Solutions to Individuals Across Poland BERKELEY, US – MAINZ, Germany – August 22, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”) , a molecular genetics diagnostic company specializing in the early detection of cancer, announces the commercial launch of ColoAlert® in Poland, made possible through a strategic collaboration with testDNA Sp. z o. o. Sp. K (“testDNA”). The partnership marks another significant step forward in providing new and innovative testing options to underserved populations in the battle against colorectal cancer (“CRC”). ColoAlert®, Mainz Biomed's flagship product is a user-friendly and highly effective at-home screenin…

The two organizations are joining forces to develop pioneering AI-based solutions for efficient chemical synthesis planning to accelerate the development of novel pharmaceuticals. COLUMBUS, Ohio & WARSAW, Poland--(BUSINESS WIRE)--CAS, a division of the American Chemical Society specializing in scientific information solutions, and Molecule.one, a tech-bio leader in AI-based solutions for pharmaceutical chemistry, have established a strategic collaboration focused on the joint development of computer-aided synthesis design technologies to accelerate scientific breakthroughs in early-stage drug discovery and aid chemists in the discovery of novel small molecules. Leveraging their existing technologies and expertise, including Molecule.one’s proprietary generative deep learning models and…

STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is pleased to announce that it will be presenting the discovery of its lead clinical candidate, STC-15, which is an orally bioavailable and highly selective METTL3 inhibitor, at the American Chemical Society (ACS) Fall 2023 Conference, in San Francisco, California on the 13-17 August 2023. The presentation entitled “Discovery of STC-15, an orally bioavailable, highly selective METTL3 inhibitor for the treatment of AML and solid tumours: The first molecule specifically targeting an RNA methyltransferase enzyme to enter clinical development” will detail the Company’s discovery effor…

Envisioning the future of regulatory and medical writing, CAPTIS Copilot leverages cutting-edge AI models for the Medical Device and Diagnostic industry. CHICAGO--(BUSINESS WIRE)--Celegence, a regulatory compliance service and software solution company, today announced the launch of CAPTIS Copilot, the most advanced document automation and literature review solution for the life sciences industry. CAPTIS Copilot is an enterprise cloud-based platform leveraging pre-trained large language models (LLM) and Reinforcement Learning from Human Feedback (RLHF) for the device and diagnostic industry. This cloud-based solution significantly advances the ability of device and IVD manufacturers to increase innovation and empower clinical, regulatory, and medical writing teams to be more strategic and…

Collaborative Partnership Strengthens Mainz Biomed's Mission to Combat Colorectal Cancer, Saving Lives through Advanced Diagnostics BERKELEY, US – MAINZ, Germany – August 01, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that London-based Marylebone Laboratory (Marylebone Lab Ltd) has introduced ColoAlert®, Mainz Biomed’s flagship product—a highly effective and user-friendly at-home detection test for colorectal cancer (CRC) - to its extensive UK and international customer base. Further strengthening Mainz Biomed’s global network of esteemed laboratory partners, the collaboration marks another significant milestone in the Company’s mission to combat colorectal ca…

Innovations created by the 24 semi-finalists include an app that helps people living with dementia communicate, high-tech facial recognition glasses to identify familiar faces, and an augmented reality map to help people safely find their way around their area. Semi-finalists will each receive £80k grants as part of the overall £4m Longitude Prize on Dementia driving the co-creation of personalised technologies to help people living with dementia enjoy independent and fulfilled lives. The Longitude Prize on Dementia is funded by Alzheimer’s Society and Innovate UK and delivered by Challenge Works. 20 June 2023 - An app that repairs “broken” speech, high-tech glasses that can help those with dementia recognise others, and a “Yellow Brick Road” map to help people navigate their community a…

WiLD is a new and fast-growing professional network for women in senior positions across industry and academia in Danish life science A key objective is to provide professional, tailored mentoring programs for women in the life science business – from young talents to executives - in critical career transitions and WiLD has received a grant from the Lundbeck Foundation to build a mentorship programme, which will be launched in September 2023 13 June 2023, Denmark: Women in Life Science Denmark (WiLD) is pleased to announce that is has been awarded a grant of EUR 63.800 from The Lundbeck Foundation to advance its mentoring program for women working in life sciences in Denmark. WiLD’s Female Leadership Mentoring Program aims to inspire the next generation of female leaders and entrepreneurs…

The company’s third commercial CAR T manufacturing facility in the U.S. further extends Bristol Myers Squibb’s leadership in cell therapy PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved commercial production at the company’s newest cell therapy manufacturing facility in Devens, Massachusetts. The Devens site is a critical component of BMS’ expanding global cell therapy manufacturing footprint for long-term supply of the company’s cell therapy portfolio. “The Devens facility integrates the latest state-of-the-art technology in the industry with top talent in the Boston area that will take us into the next phase of our cell therapy journey,” said Karin Shanahan, executive vice president, Globa…

Now in its 11th year, MedTech Innovator continues to identify the best medical device, diagnostic and digital health startups developing innovative tools to improve patient care LOS ANGELES--(BUSINESS WIRE)--#innovator--MedTech Innovator, the world’s largest accelerator of medical technology companies, today announced the 2023 Accelerator Cohort. After a competitive selection process, 61 companies were chosen to participate in the MedTech Innovator’s flagship four-month MedTech Accelerator program. Featuring medical device, diagnostic, and digital health companies from around the globe, the 2023 Cohort members will get unparalleled visibility and access to leading medtech manufacturers, providers, investors, and other industry stakeholders. MedTech Innovator will additionally award $800,00…

Thermo Scientific Orbitrap Astral mass spectrometer combines high resolution and speed to accelerate the discovery of new proteins and advance precision medicine WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today unveiled the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, one of the most significant advancements in mass spectrometry in 15 years. The new Astral analyzer combines fast throughput, high sensitivity and deep proteome coverage to allow researchers worldwide to uncover proteins that previously evaded detection and make breakthrough discoveries more efficiently than ever. Researchers can use this information to identify new clinical biomarkers, reveal diseases earlier and develop new interventions for eve…

Facility will have capacity that exceeds today’s global plasmid DNA demand and can enable commercialisation of genetic medicines. Transformation of Grade II-listed Victorian waterworks on the River Thames in Hampton, London. Supplying many of the top biopharmaceutical companies in the world to dramatically enhance their ability to develop genetic medicines. Expansion follows recent acceptance of a Drug Master File and first investigational new drug application using doggybone DNA. Hampton, UK, 24 May 2023 – Touchlight, a company pioneering enzymatic DNA production, a critical material in many new genetic medicine treatments, has completed the redevelopment and expansion of its UK manufacturing facility, housed in a repurposed Victorian waterworks on the banks of the River Thames. The exp…

Accelerate@Babraham, the Babraham Research Campus’ programme supporting early-stage life science ventures, announces new cohort  Cambridge, UK, 16th May 2023: Babraham Research Campus Ltd, which is responsible for the development and management of the Babraham Research Campus is delighted to officially welcome six new ventures to Accelerate@Babraham 2023. Chosen via a rigorous selection process which culminated in short-listed companies being interviewed by representatives of the Babraham Research Campus executive team and all the programme’s strategic partners, the six winning ventures are: Aila Biotech – Co-Founders, James Dooley and Adrian Liston Aila Biotech is developing a unique biologic therapy with promising pre-clinical efficacy in neuroinflammation that has been validated in mult…

AmplifyBio is adding manufacturing services, starting with cell therapy and plasmids, to its growing capabilities to support the safe development of advanced therapies. WEST JEFFERSON, Ohio, May 15, 2023 (Newswire.com) - AmplifyBio, an emerging hub for the commercialization of advanced therapies, has announced the addition of cell therapy and plasmid manufacturing capabilities to its leading portfolio of preclinical CRO and drug characterization services. The GMP cell therapy and plasmid manufacturing labs, available in South San Francisco, are the latest step in AmplifyBio's broader strategy to build a development environment that de-risks the commercialization of next-generation therapeutics.  AmplifyBio recently acquired from PACT Pharma, Inc, a privately held biopharmaceutical company…

Bern, Switzerland and Boston, U.S.A., 21 April, 2023 – RetinAI Medical AG (“RetinAI”), a leader in clinical and imaging data management software and advanced analytics using artificial intelligence (AI) for ophthalmology, is excited to announce a new partnership with Boehringer Ingelheim. The companies aim to improve patient outcomes in geographic atrophy (GA) by combining RetinAI’s Discovery® platform and AI tools with Boehringer Ingelheim’s research in retinal diseases. GA is a progressive, advanced form of age-related macular degeneration and a leading cause of complete loss of sight, estimated to affect around 5 million people worldwide1. The number of people affected by GA increases exponentially with age. As the population ages, the prevalence of the disease is expected to rise.1,2 T…

Basildon, UK,  27 March 2023 - Pharmanovia, a global pharmaceutical company that revitalises, extends and expands the lifecycle of established medicines, has today announced that it has expanded its exclusive licence and supply agreement with Aquestive Therapeutics, Inc. (NASDAQ: AQST) for its patented diazepam buccal film formulation to cover rest of the world, excluding US, Canada and China. Aquestive Therapeutics has been granted tentative approval by the US Food and Drug Administration (FDA)1, for its diazepam buccal film for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older. In addition to…

WALTHAM, Mass. & SAN FRANCISCO--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and the University of California, San Francisco (UCSF), will accelerate advanced cell therapies for difficult to treat conditions, including cancer, rare diseases, and other illnesses, from a newly opened cGMP manufacturing facility adjacent to UCSF Medical Center’s Mission Bay campus. The partnership between Thermo Fisher and UCSF, first announced in 2021, has the potential to demonstrate that having scientists, clinicians, and patients closer to a manufacturing site may expedite the development of breakthrough treatments. UCSF’s initial focus at the facility will be on treatments for glioblastoma, multiple myeloma, and other cancers using updated approache…